XML 41 R17.htm IDEA: XBRL DOCUMENT
v3.20.1

Mutual Covenant-Not-to-Sue and Release Agreement | 3 Months Ended
--- | ---
Mar. 31, 2020
Mutual Covenant-Not-to-Sue Agreement [Abstract] |
MUTUAL COVENANT-NOT-TO-SUE AND RELEASE AGREEMENT | MUTUAL COVENANT-NOT-TO-SUE AND RELEASE AGREEMENT In January 2020, we entered into an agreement with a competitor in the network security industry whereby, in February 2020, the competitor party paid us a lump sum of $50.0 million for a seven-year mutual covenant-not-to-sue for patent claims. Pursuant to this agreement, at the end of this first seven-year period, either party may extend the agreement for an additional seven-year mutual covenant-not-to-sue in return for this competitor paying us an additional $50.0 million. This agreement arose after expiration of previous agreements between the parties whereby the competitor had paid us sums for a limited term license to certain of our intellectual property (“IP”) and a limited term mutual covenant-not-to-sue. We concluded that the agreement was a 14-year contract with a total transaction price of $100.0 million, and that it contained two material distinct performance obligations: (1) the right to use our existing patents, and (2) the right to use any patents that we develop over the term of the contract. We allocated $36.0 million to the functional patents, which was recognized upon commencement of the contract; the remaining $64.0 million, representing the right to utilize future patents, will be recognized over the contract term. We further concluded that our existing patents represent functional IP that should be recognized upon granting our competitor access. We also concluded that the right to receive additional functional IP that we will develop in the future represents a stand ready obligation. Therefore, the transaction price allocated to this obligation is recognized ratably over the 14-year contract term. We estimated the stand-alone selling price of each distinct performance obligation and allocated the $100.0 million transaction price. During the three months ended March 31, 2020, we recorded $36.8 million in Gain on IP matter in our condensed consolidated statement of income, consisting of the $36.0 million allocated to the functional patents and $0.8 million of amortization of the deferred component. We recorded $13.2 million in Accrued liabilities and Other liabilities in our condensed consolidated balance sheet as of March 31, 2020.

X
- Definition Mutual Covenant-Not-to-Sue Agreement [Abstract] + References No definition available. + Details
Name: | ftnt_MutualCovenantNottoSueAgreementAbstract
Namespace Prefix: | ftnt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Mutual Covenant-Not-to-Sue Agreement Disclosure [Text Block] + References No definition available. + Details
Name: | ftnt_MutualCovenantNottoSueAgreementDisclosureTextBlock
Namespace Prefix: | ftnt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration